Login to Your Account



Nuvox's stroke candidate could triple window of time compared to tPA

By Michael Fitzhugh
Staff Writer

Tuesday, August 23, 2016

Chasing improved safety and decreased brain damage for stroke sufferers, Nuvox Pharma LLC is preparing for a fourth quarter start to a phase Ib study of NVX-208, one of multiple oxygen therapeutics the company is advancing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription